
Ocugen Inc OCGN.OQ OCGN.O is expected to show a fall in quarterly revenue when it reports results on May 9 for the period ending March 31 2025
LSEG's mean analyst estimate for Ocugen Inc is for a loss of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.
Wall Street's median 12-month price target for Ocugen Inc is $7.50, above its last closing price of $0.72.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.04 | -0.05 | -0.05 | Met | 4.8 |
Sep. 30 2024 | -0.06 | -0.05 | -0.05 | Met | 6.2 |
Jun. 30 2024 | -0.05 | -0.05 | -0.04 | Beat | 25 |
Mar. 31 2024 | -0.06 | -0.06 | -0.05 | Beat | 21 |
Dec. 31 2023 | -0.06 | -0.03 | Beat | 53.8 | |
Sep. 30 2023 | -0.07 | -0.07 | -0.06 | Beat | 14.3 |
Jun. 30 2023 | -0.07 | -0.07 | -0.08 | Missed | -9.1 |
Mar. 31 2023 | -0.11 | -0.11 | -0.07 | Beat | 35.2 |
This summary was machine generated May 7 at 12:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)